To further reduce the potential for immunogenicity in humans, we plan to use just the human anti-GPC3 F(ab’)2 portion (alone or engrafted onto human IgG1 Fc) for subsequent evaluation in our orthotopic HCC PDX models, and for pharmacokinetics and toxicity studies of anti-GPC3 F(ab’)2 and its resulting conjugate with DOTA-Gd, especially under repeated dosing conditions. This evidence concerns the gene GPC3 and hepatocellular carcinoma.